Filing Analysis
Oleg Nodelman has resigned from the Board of Directors of Prothena Corporation, effective December 31, 2024. The resignation is reportedly to allow him to focus on other endeavors and was not due to any disagreement with the company.
📋 Key Facts
- Oleg Nodelman will resign from the Board of Directors effective December 31, 2024.
- The departure is intended to allow the director time to focus on existing and new endeavors.
- Nodelman will continue serving on the Compensation Committee and Nominating and Corporate Governance Committee through his effective date.
- The company explicitly states there was no disagreement regarding operations, policies, or practices.
Prothena Corporation announced its financial results for the third quarter ended September 30, 2024. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Third Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing the financial results.
Prothena Corporation announced the resignation of its Chief Medical Officer, Hideki Garren, M.D., Ph.D., effective September 27, 2024. Dr. Garren is leaving to pursue an opportunity at a large pharmaceutical company.
🚩 Red Flags
- Departure of a key executive (Chief Medical Officer) in the biotechnology sector can impact clinical development momentum and investor confidence.
📋 Key Facts
- Hideki Garren, M.D., Ph.D., resigned as Chief Medical Officer on September 23, 2024.
- The resignation becomes effective on September 27, 2024.
- Reason for departure: To pursue an opportunity at a large pharmaceutical company.
Prothena Corporation announced its financial results for the second quarter ended June 30, 2024. The filing serves as a formal notification of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024
- Filing date: August 8, 2024
- The filing is an announcement of financial results under Item 2.02.
Prothena Corporation has entered into a Global License Agreement with Bristol Myers Squibb (BMS) regarding the PRX019 research program. The agreement grants BMS exclusive global rights to develop and commercialize antibody products targeting specified targets, involving significant upfront and milestone payments.
🚩 Red Flags
- Milestone payments and royalties are subject to reductions if BMS develops improved versions of the product.
- BMS retains rights to terminate the agreement for certain safety reasons.
📋 Key Facts
- BMS exercised its IND Option for the PRX019 research program.
- Prothena receives an upfront payment of $80 million.
- Potential development/regulatory milestones totaling up to $242.5 million.
- Potential sales-based milestones totaling up to $375 million.
- Tiered royalties ranging from high single digits to high teens on net sales.
- Prothena is obligated to run the Phase 1 clinical trial for PRX019, though BMS has the option to take over this responsibility.
Prothena Corporation held its Annual General Meeting on May 14, 2024. Shareholders approved an amendment to the 2018 Long Term Incentive Plan (LTIP) and re-elected several directors.
📋 Key Facts
- Annual Meeting held on May 14, 2024.
- Shareholders approved an amendment to the 2018 LTIP, increasing authorized shares for issuance by 2,000,000 ordinary shares.
- Four directors (Richard T. Collier, Shane M. Cooke, William H. Dunn, Jr., and Daniel G. Welch) were re-elected to terms ending in 2027.
- Shareholders ratified the appointment of KPMG LLP as independent auditor for fiscal year 2024.
- Shareholders approved executive compensation via a non-binding advisory vote.
Prothena Corporation issued an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notice that the quarterly earnings press release is being furnished to the SEC.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024.
- Announcement date: May 8, 2024.
- The filing includes a press release (Exhibit 99.1) regarding results of operations and financial condition.
Prothena Corporation announced the appointment of Daniel G. Welch to the Board of Directors, effective February 21, 2024. Mr. Welch will serve as Chair Designate and is expected to become Chair of the Board following shareholder election at the next annual meeting.
📋 Key Facts
- Daniel G. Welch appointed to the Board of Directors on February 21, 2024.
- Welch designated as 'Chair Designate' with intent to assume Chair role after shareholder election.
- Granted an option to acquire 132,000 ordinary shares under the 2018 Long Term Incentive Plan.
- Option exercise price set at the last reported sale price on Nasdaq as of February 21, 2024.
- Options vest in equal annual installments over five years subject to continuous service.
- Annual cash retainer of $90,000 for service as Chair Designate and subsequent Chair.
Prothena Corporation announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. This is a routine earnings release filing.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023.
- Filing date: February 15, 2024.
- The report includes the announcement of financial results via a press release (Exhibit 99.1).
Prothena Corporation announced preliminary financial results for the period ending December 31, 2023. The company expects to report approximately $621 million in cash, cash equivalents, and restricted cash.
📋 Key Facts
- Expected cash, cash equivalents, and restricted cash: ~$621 million as of Dec 31, 2023.
- The announcement was made on January 8, 2024.
- Preliminary estimate based on currently available information; final figures subject to year-end audit/closing.